[3H]-YM-09151-2 binding sites in human brain postmortem

The controversial and limited data on the distribution of dopamine (DA) receptors of type 4 (D(4)) in the human brain prompted us to explore their density and pharmacological characteristics in the prefrontal cortex, striatum and hippocampus, through a series of binding assays. Brain samples were taken during autopsy from seven subjects. Tissue homogenates were incubated with increasing concentration of [(3)H]-YM-09151-2, a D(2)-like receptor antagonist, and L-745,870 and/or sulpiride to define the non-specific binding, while PPAP was used to block sigma receptors. The results showed a low density of D(4) receptors in the hippocampus only, with a preponderance of D(2)/D(3) and sigma receptors in the prefrontal cortex and striatum. In conclusion, these findings underline that it is possible to label D(4) receptors by means of [(3)H]-YM-09151-2, provided that D(2), D(3) and sigma receptors are blocked.

[1]  F. Tarazi,et al.  Dopamine D4 Receptors: Beyond Schizophrenia , 2004, Journal of receptor and signal transduction research.

[2]  J. Tallman,et al.  II. Localization and characterization of dopamine D4 binding sites in rat and human brain by use of the novel, D4 receptor-selective ligand [3H]NGD 94-1. , 1997, The Journal of pharmacology and experimental therapeutics.

[3]  M. Matsumoto,et al.  Low Levels of mRNA for Dopamine D4 Receptor in Human Cerebral Cortex and Striatum , 1996, Journal of neurochemistry.

[4]  Steven G. Potkin,et al.  Decrease in σ but no increase in striatal dopamine D4 sites in schizophrenic brains , 1996 .

[5]  J. Potash,et al.  Mood disorder with psychotic features, schizoaffective disorder, and schizophrenia with mood features: Trouble at the borders , 2005, International review of psychiatry.

[6]  P. Muglia,et al.  Dopamine D4 receptor and tyrosine hydroxylase genes in bipolar disorder: evidence for a role of DRD4 , 2002, Molecular Psychiatry.

[7]  A. Rivera,et al.  Differential regional and cellular distribution of dopamine D2‐like receptors: An immunocytochemical study of subtype‐specific antibodies in rat and human brain , 1998, The Journal of comparative neurology.

[8]  P. Leeson,et al.  L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests. , 1997, The Journal of pharmacology and experimental therapeutics.

[9]  R. Kerwin,et al.  Elevation of D4 dopamine receptor mRNA in postmortem schizophrenic brain. , 1998, Brain research. Molecular brain research.

[10]  H. Akil,et al.  Inhibition of cell surface expression by mutant receptors demonstrates that D2 dopamine receptors exist as oligomers in the cell. , 2000, Molecular pharmacology.

[11]  G A McPherson,et al.  Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC. , 1985, Journal of pharmacological methods.

[12]  F. Jursky,et al.  Truncation of human dopamine transporter by protease calpain , 2008, Neurochemistry International.

[13]  J. Massagué.  TGF-beta signal transduction. , 1998, Annual review of biochemistry.

[14]  H. Meltzer,et al.  An overview of the mechanism of action of clozapine. , 1994, The Journal of clinical psychiatry.

[15]  D. Helmeste,et al.  Dopamine D4 receptors. , 2000, Japanese journal of pharmacology.

[16]  P. Seeman,et al.  Low density of dopamine D4 receptors in Parkinson's, schizophrenia, and control brain striata , 1993, Synapse.

[17]  R. Conley,et al.  Direct determination of dopamine D4 receptors in normal and schizophrenic postmortem brain tissue: a [3H]NGD-94-1 study , 1998, Molecular Psychiatry.

[18]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[19]  Stanley J Watson,et al.  Dopamine Receptor mRNA Expression in Human Striatum and Neocortex , 1996, Neuropsychopharmacology.

[20]  R. Kerwin,et al.  No difference in the expression of the D4 gene in post-mortem frontal cortex from controls and schizophrenics , 1996, Neuroscience Letters.

[21]  H. Ujike,et al.  [3H]YM‐09151–2 (nemonapride), a potent radioligand for both sigma1 and sigma2 receptor subtypes , 1996, Neuroreport.

[22]  M. Brockhaus,et al.  Development and Characterization of Antibodies Against the N Terminus of the Human Dopamine D4 Receptor , 1997, Journal of neurochemistry.

[23]  P. Deyn,et al.  The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia , 2008, Neurochemistry International.

[24]  F. Tarazi,et al.  Dopamine D4 receptors: significance for molecular psychiatry at the millennium , 1999, Molecular Psychiatry.

[25]  F. Tarazi,et al.  Localization of dopamine receptor subtypes in corpus striatum and nucleus accumbens septi of rat brain: comparison of D1-, D2- and D4-like receptors , 1998, Neuroscience.

[26]  M. Bergström,et al.  N-[11C]Methylspiperone PET, in contrast to [11C]raclopride, fails to detect D2 receptor occupancy by an atypical neuroleptic , 1998, Psychiatry Research: Neuroimaging.

[27]  K. Davis,et al.  Dopamine in schizophrenia: a review and reconceptualization. , 1991, The American journal of psychiatry.

[28]  S. Potkin,et al.  Differential labeling of dopamine and sigma sites by [3H]nemonapride and [3H]raclopride in postmortem human brains , 1997, Brain Research.

[29]  P. Seeman,et al.  Dopamine D4 receptors elevated in schizophrenia , 1993, Nature.

[30]  J. Russell,et al.  Neurobiology of depression: an integrated view of key findings , 2007, International journal of clinical practice.

[31]  E G Jones,et al.  Decrease in sigma but no increase in striatal dopamine D4 sites in schizophrenic brains. , 1996, European journal of pharmacology.

[32]  D. Sibley,et al.  Molecular biology of dopamine receptors. , 1992, Trends in pharmacological sciences.

[33]  R. De La Garza,et al.  [3H]PNU‐101958, a D4 dopamine receptor probe, accumulates in prefrontal cortex and hippocampus of non‐human primate brain , 2000, Synapse.

[34]  B. Dell’Osso,et al.  Presence of D4 dopamine receptors in human prefrontal cortex: a postmortem study. , 2007, Revista brasileira de psiquiatria.

[35]  I. Creese,et al.  Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs. , 1997, The Journal of pharmacology and experimental therapeutics.

[36]  A. Newman-Tancredi,et al.  Differential in vivo Inhibition of [3H]Nemonapride Binding by Atypical Antipsychotics in Rat Striatum, Olfactory Lobes, and Frontal Cortex , 2005, Pharmacology.

[37]  Ming Li,et al.  Multiple [3H]-nemonapride binding sites in calf brain , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[38]  Glenda M MacQueen,et al.  Course of illness, hippocampal function, and hippocampal volume in major depression , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[39]  H. V. Van Tol,et al.  The dopamine D(4) receptor: one decade of research. , 2000, European journal of pharmacology.

[40]  J. Deakin,et al.  The relative abundance of dopamine D4 receptor mRNA in post mortem brains of schizophrenics and controls , 1996, Schizophrenia Research.